A Phase I Study of MK0752, a Notch Inhibitor, in Patients With Metastatic or Locally Advanced Breast Cancer and Other Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 21 Apr 2014
At a glance
- Drugs MK 0752 (Primary)
- Indications Advanced breast cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 24 Apr 2012 Actual patient number (103) added as reported by ClinicalTrials.gov.
- 07 Sep 2011 Actual end date (August 2011) added as reported by ClinicalTrials.gov.
- 07 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.